HomeAI · summaries
Storia in 2 fonti
A $10B deal, China trial scrutiny and highlights from ADA 2026
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. | This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with CSPC Pharmaceutical and Sino Biopharmaceutical,…
- ·
A $10B deal, China trial scrutiny and highlights from ADA 2026
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. | This…
